Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers - ADME

Study identifier:D0520C00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Single-Centre, Phase I Study to Assess the Excretion, Metabolism and Plasma Pharmacokinetics following a Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

[C14]AZD9668

Sex

Male

Actual Enrollment

Study type

Interventional

Age

50 Years +

Date

Study Start Date: 01 Jun 2010

Primary Completion Date: 01 Jul 2010

Study Completion Date: 01 Jul 2010

Study design

Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Experimental: 1 [C14]AZD9668	Drug: [C14]AZD9668 Oral Solution 60 mg Single Dose

"There is no result for the study"

Documents available

Cancer Study Locator (US and Canada only)
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1653&filename=CSR-D0520C00016.pdf
Download
CSR-D0520C00016.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Quintiles London

+ 44 0800 634 1132

Investigators

Principal Investigator

Chris O'Brien

AstraZeneca R&D, Wilmington